Baricitinib, Free Base

Baricitinib, Free Base
Item number Size Datasheet Manual SDS Delivery time Quantity Price
LC-B-1600_10mg 10 mg -

3 - 15 business days*

71.00€
LC-B-1600_25mg 25 mg -

3 - 15 business days*

80.00€
LC-B-1600_50mg 50 mg -

3 - 15 business days*

93.00€
LC-B-1600_100mg 100 mg -

3 - 15 business days*

106.00€
LC-B-1600_200mg 200 mg -

3 - 15 business days*

120.00€
LC-B-1600_500mg 500 mg -

3 - 15 business days*

192.00€
LC-B-1600_1g 1 g -

3 - 15 business days*

309.00€
LC-B-1600_2g 2 g -

3 - 15 business days*

479.00€
LC-B-1600_5g 5 g -

3 - 15 business days*

847.00€
 
Soluble in DMSO. Baricitinib, also known as INCB028050, is a janus kinase (JAK) inhibitor. It... more
Product information "Baricitinib, Free Base"
Soluble in DMSO. Baricitinib, also known as INCB028050, is a janus kinase (JAK) inhibitor. It potently and selectively inhibited JAK1 and JAK2 kinases with IC50 values of 5.9 nM and 5.7 nM, respectively. It inhibited intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23, with IC50 values of <50 nM. Baricitinib at doses providing partial and/or periodic inhibition of JAK1/JAK2 significantly improved rheumatoid arthritis as assessed by clinical, histologic and radiographic signs of disease in the rat adjuvant arthritis model. It was also effective in multiple murine models of arthritis. Fridman J.S., et al. 'Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.' J. Immunol. 184: 5298-5307 (2010). Baricitinib was well tolerated and demonstrated clinically meaningful responses in patients with active rheumatois arthritis. Greenwald M.W., et al. 'A Randomized Dose-Ranging, Placebo-Controlled Study of INCB028050, a Selective JAK1 and JAK2 Inhibitor in Subjects with Active Rheumatoid Arthritis.' http://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=774&id=90814. Baricitinib reversed alopecia areata in in vivo preclinical studies and in patients. Jabbari A., et al. 'Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.' EBioMedicine. 2: 351-355 (2015).
Keywords: NCB028050, LY3009104
Supplier: LC Laboratories
Supplier-Nr: B-1600

Properties

Application: Antiinflammatory, Antirheumatic, Immunosuppressant, Janus kinase (JAK) inhibitor
MW: 371.42 D
Formula: C16H17N7O2S
Purity: >99%
Format: Solid

Database Information

CAS : 1187594-09-7| Find alternatives
KEGG ID : K11217 | Find alternatives

Handling & Safety

Storage: -20°C
Shipping: +20°C (International: +20°C)
Signal Word: Warning
GHS Hazard Pictograms:
H Phrases: H302+312+332
P Phrases: P262
Caution
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow. more
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "Baricitinib, Free Base"
Write a review
or to review a product.
Viewed